1. Home
  2. TYRA vs STRA Comparison

TYRA vs STRA Comparison

Compare TYRA & STRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$33.74

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

STRA

Strategic Education Inc.

HOLD

Current Price

$79.80

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYRA
STRA
Founded
2018
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
TYRA
STRA
Price
$33.74
$79.80
Analyst Decision
Strong Buy
Buy
Analyst Count
11
3
Target Price
$47.50
$87.00
AVG Volume (30 Days)
749.1K
285.9K
Earning Date
05-06-2026
04-23-2026
Dividend Yield
N/A
3.04%
EPS Growth
N/A
15.85
EPS
N/A
1.48
Revenue
N/A
$997,137,000.00
Revenue This Year
N/A
$4.71
Revenue Next Year
N/A
$4.67
P/E Ratio
N/A
$54.13
Revenue Growth
N/A
57.23
52 Week Low
$8.75
$69.70
52 Week High
$40.65
$92.98

Technical Indicators

Market Signals
Indicator
TYRA
STRA
Relative Strength Index (RSI) 43.61 51.25
Support Level $33.29 $78.41
Resistance Level $33.99 $84.97
Average True Range (ATR) 1.98 2.13
MACD -0.02 0.32
Stochastic Oscillator 30.44 60.51

Price Performance

Historical Comparison
TYRA
STRA

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About STRA Strategic Education Inc.

Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.

Share on Social Networks: